Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, reflects on the impact of HER2 identification on the breast cancer ...

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical ...

New data highlight efficacy, safety, and time off treatment with as-needed ruxolitinib cream in pediatric atopic dermatitis.

Adult patients with moderate to severe hand eczema with previous treatment failure or in whom topical corticosteroids are ...

Mother-to-child transmission often led to pretreatment drug resistance and acquired drug resistance in children living with ...

The FDA’s approval of linvoseltamab for adults with heavily pretreated relapsed/refractory multiple myeloma marks a significant advance, with Sundar Jagannath, MBBS, emphasizing its high response ...

Culturally informed, patient-centered strategies are needed to address acne and hyperpigmentation in patients with skin of color.

State governments must have budgetary and regulatory flexibility to support health care innovation, says Sen. Vincent Polistina (R, New Jersey).

An expert discusses how long-term safety considerations are evaluated through clinical trial data and postmarketing ...

Rebecca Chacko, MD, discussed exciting advancements in breast cancer care and the future role of emerging therapeutic strategies for early recurrence detection, as part of her panelist role at the ...

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice ...